{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:28:02Z","timestamp":1783524482206,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFF1202600"],"award-info":[{"award-number":["2022YFF1202600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2024ZZ1010"],"award-info":[{"award-number":["2024ZZ1010"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22371188"],"award-info":[{"award-number":["22371188"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["25ZR1401331"],"award-info":[{"award-number":["25ZR1401331"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118203","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:02:33Z","timestamp":1759006953000},"page":"118203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of novel potent indazole-based FXR agonists via scaffold hopping for MASH treatment"],"prefix":"10.1016","volume":"301","author":[{"given":"Da-Yu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5368-6876","authenticated-orcid":false,"given":"Dingding","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118203_bib1","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"26","author":"Negi","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2025.118203_bib2","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118203_bib3","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s41564-023-01418-7","article-title":"Parabacteroides distasonis uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid","volume":"8","author":"Wei","year":"2023","journal-title":"Nat. Microbiol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118203_bib4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2022.11.025","article-title":"A phase I\/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis","volume":"78","author":"Mak","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118203_bib5","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3390\/cells9071638","article-title":"Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease","volume":"9","author":"Fougerat","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118203_bib6","doi-asserted-by":"crossref","first-page":"8255","DOI":"10.1093\/nar\/gkaa615","article-title":"Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD\/NASH","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118203_bib7","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2025.118203_bib8","article-title":"Epigenetics in NAFLD\/NASH: targets and therapy","volume":"167","author":"Nalini","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118203_bib9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"Opean association for the study of the liver (EASL); European Association for the Study of Diabetes (EASD); European AsEASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118203_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejmech.2025.118203_bib11","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/cells9041005","article-title":"Noninvasive diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118203_bib12","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3390\/cells13231949","article-title":"The molecular mechanism of farnesoid X receptor alleviating glucose intolerance in turbot (Scophthalmus maximus)","volume":"13","author":"Qin","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118203_bib13","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.csbj.2021.04.029","article-title":"Farnesoid X receptor (FXR): structures and ligands","volume":"19","author":"Jiang","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118203_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612748","article-title":"Current therapeutical approaches targeting lipid metabolism in NAFLD","volume":"24","author":"Vitulo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118203_bib15","first-page":"1519","article-title":"Transcriptional regulation of metabolic pathways via lipid-sensing nuclear receptors PPARs, FXR, and LXR in NASH, cell mol","volume":"11","author":"Cariello","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118203_bib16","first-page":"1","article-title":"SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis","volume":"240","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118203_bib17","first-page":"1","article-title":"Molecular tuning of farnesoid X receptor partial agonism","volume":"2915","author":"Merk","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118203_bib18","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1038\/s41467-023-42702-8","article-title":"Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis","volume":"14","author":"Tschuck","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118203_bib19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.3390\/molecules24061043","article-title":"Introduction of nonacidic side chains on 6-Ethylcholane scaffolds in the identification of potent bile acid receptor agonists with improved pharmacokinetic properties","volume":"24","author":"Finamore","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118203_bib20","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.apsb.2024.02.017","article-title":"A combined nanotherapeutic approach targeting farnesoid X receptor, ferroptosis, and fibrosis for nonalcoholic steatohepatitis treatment","volume":"14","author":"Fu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118203_bib21","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1016\/j.cell.2024.10.001","article-title":"Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118203_bib22","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"NASH clinical research network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.118203_bib23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s42004-020-00411-z","article-title":"A triple farnesoid X receptor and peroxisome proliferator-activated receptor \u03b1\/\u03b4 activator reverses hepatic fibrosis in diet-induced NASH in mice","volume":"3","author":"Heitel","year":"2020","journal-title":"Commun. Chem."},{"key":"10.1016\/j.ejmech.2025.118203_bib24","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jhep.2023.07.034","article-title":"FXR agonists in NASH treatment","volume":"79","author":"Adorini","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118203_bib25","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118203_bib26","first-page":"802","article-title":"Pipeline of new drug treatment for non-alcoholic fatty liver disease\/metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Hu","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118203_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/biom15010121","article-title":"Current treatment regimens and promising molecular therapies for chronic hepatobiliary diseases","volume":"15","author":"Durazzo","year":"2025","journal-title":"Biomolecules"},{"issue":"21","key":"10.1016\/j.ejmech.2025.118203_bib28","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118203_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejmech.2018.05.007","article-title":"From hit to lead: structure-based discovery of naphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4","volume":"154","author":"Gao","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118203_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/acs.jmedchem.2c01202","article-title":"Discovery of novel drug-like PHGDH inhibitors to disrupt serine biosynthesis for cancer therapy","volume":"66","author":"Gao","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:26:33Z","timestamp":1773134793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"alternative-id":["S0223523425009687"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118203","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel potent indazole-based FXR agonists via scaffold hopping for MASH treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118203"}}